Trimeris T-1249
Executive Summary
FDA grants "fast track" designation to the company's second HIV fusion inhibitor, which blocks the fusion of HIV with host cells. Phase I trials for T-1249 are scheduled to begin during second quarter 1999. T-20, which is currently in Phase II clinical trials, has also received fast track designation